US 12,290,611 B2
Cell or tissue embedding device
Akinobu Oharuda, Sakai (JP); Yoshihiro Kimura, Sakai (JP); and Masafumi Goto, Sendai (JP)
Assigned to Japan Vam & Poval Co., Ltd., Osaka (JP); and National University Corporation Tohoku University, Miyagi (JP)
Filed by Japan Vam & Poval Co., Ltd., Sakai (JP); and National University Corporation Tohoku University, Sendai (JP)
Filed on May 2, 2023, as Appl. No. 18/310,787.
Application 18/310,787 is a continuation of application No. 16/487,400, granted, now 11,684,693, previously published as PCT/JP2018/006661, filed on Feb. 23, 2018.
Prior Publication US 2023/0263936 A1, Aug. 24, 2023
Int. Cl. A61L 27/16 (2006.01); A61L 27/34 (2006.01); A61L 27/38 (2006.01); A61L 27/54 (2006.01); C12M 3/00 (2006.01); C12N 5/071 (2010.01)
CPC A61L 27/16 (2013.01) [A61L 27/34 (2013.01); A61L 27/3804 (2013.01); A61L 27/54 (2013.01); C12M 21/08 (2013.01); C12N 5/0671 (2013.01); C12N 5/0677 (2013.01); A61L 2300/412 (2013.01); A61L 2300/606 (2013.01); A61L 2300/64 (2013.01); A61L 2400/18 (2013.01); A61L 2420/02 (2013.01); A61L 2430/28 (2013.01); A61L 2430/40 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A cell or tissue embedding device having an aqueous gel serving as an immunoisolation layer, the aqueous gel containing, as components thereof, a denatured polyvinyl alcohol resin having an activated carbonyl group and a crosslinking agent wherein the device is configured to be implanted in a subject, and wherein the cells or tissue are not from living microorganisms, wherein the crosslinking agent is a hydrazide compound and/or a semicarbazide compound.